AstraZeneca and Bristol Myers Squibb Reportedly Discussing $400 Billion Merger
AstraZeneca and Bristol Myers Squibb are reportedly in talks regarding a potential $400 billion merger, which would create one of the world's largest pharmaceutical companies. Following the reports, AstraZeneca's shares experienced a significant drop.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (92/100)Sources
AstraZeneca shares slide 7% after reports of Bristol Myers talks - Reuters
AstraZeneca shares slide 7% after reports of Bristol Myers talks Reuters
Read full article →AstraZeneca Is Said to Have Explored Bristol Myers Merger
AstraZeneca has explored an acquisition of Bristol Myers Squibb, according to people familiar with the matter. It’s unclear if discussions are ongoing or whether they will result in a transaction, the people cautioned. A representative for AstraZeneca declined to comment and Bristol Myers Squibb couldn’t immediately be reached for comment on the talks. Bloomberg's Manuel Baigorri reports. (Source: Bloomberg)
Read full article →AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks - WSJ
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks WSJ
Read full article →FirstFT: AstraZeneca and Bristol Myers Squibb discuss $400bn tie-up
Also in today’s newsletter: Ceuta migrant crossing and Uefa’s response to failed Fifa plan
Read full article →AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group. AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn. BMS, headquartered in Princeto...
By Julia Kollewe
Read full article →AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.
Read full article →AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
By Steve Goldstein
Read full article →AstraZeneca in talks over £300bn mega-merger with US rival – reports
The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.
By Henry Saker-Clark
Read full article →AstraZeneca plots £300bn tie-up with US rival
Read full article →AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker
By Kelly Gilblom
Read full article →
